Parameters influencing measurement of the gag antigen-specific T- proliferative response to HIV type 1 infection

AIDS Research and Human Retroviruses

Volumn 16, Issue 3, 2000, Pages 259-271

  Schiller, Daryl S ^a   Binley, James M ^a   Roux, Kenneth H ^b   Adamson, Catherine S ^c   Jones, Ian M ^c   Krausslich, Hans Georg ^d   Hurley, Arlene ^a   Markowitz, Martin ^a   Moore, John P ^a,e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c NATURAL ENVIRONMENT RESEARCH COUNCIL   (United Kingdom)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^e AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CAPSID PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEASUREMENT; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; CAPSID; CAPSID PROTEINS; CELL DIVISION; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FREEZING; GENE PRODUCTS, GAG; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROSCOPY, ELECTRON; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; TIME FACTORS; VIRAL PROTEINS;

EID: 0034628609     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309359     Document Type: Article

References (40)

1. 1. Johnson RP, Siliciano RF, and McElrath MJ: Cellular immune responses to HIV-1. AIDS 1998;12:S113-S120.
2. 2. Rosenberg ES and Walker BD: HIV type 1-specific helper T cells: A critical host defense. AIDS Res Hum Retroviruses 1998;14: S143-S147.
3. 3. Lane HC, Masur H, Edgar LC, Whalen G, Rook AR, and Fauci AS: Abnormalities of B cell activation and immunoregulation in patients with the acquired immune deficiency syndrome. N Engl J Med 1983;309:453-458.
4. + cells and and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis 1988;158:615-622.
5. 5. Janeway CA Jr and Bottomly K: Signals and signs for lymphocyte responses. Cell 1994;76:275-285.
6. + T cell-mediated antiviral protection. J Immunol 1999;162:2867-2874.
7. + T cell responses associated with control of viremia. Science 1998; 278:1447-1450.
8. 8. Plana M, Garcia F, Gallart T, Miro JM, and Gatell JM: Lack of T cell proliferative response to HIV antigens after 1 year of HAART in early HIV-1 disease. Lancet 1998;352:1194-1195.
9. 9. Goujard C, Taoufik Y, Wallon C, Lecointe D, and Delfraissy JF: HIV-1 specific CD4+ T cell response is not restored after 28 months of HAART with viral load <50 copies. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, January 1999. [Abstract 343]
10. 10. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, and Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
11. 11. Caruso A, Licenziati S, Canaris AD, Corulli M, De Francesco MA, Cantalamessa A, Fallacara F, Fiorentini S, Balsari A, and Turano A: T cells from individuals in advanced stages of HIV-1 infection do not proliferate but express activation antigens in response to HIV-1 specific antigens. J Acquir Immune Defic Syndr 1997;15:61-69.
12. 12. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497.
13. 13. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, and Gallo RC: Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850.
14. 14. Clerici M, Stocks N, Zajac RA, Boswell RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989;84:1892-1899.
15. 15. Schrier RD, Gnann JW, Landes R, Lockshin C, Richman D, McCutchan A, Kennedy C, Oldstone MBA, and Nelson JA: T cell recognition of HIV synthetic peptides in a natural infection. J. Immunol 1989;142:1166-1176.
16. 16. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, and Autran B : Long-lasting recovery of CD4 T cell function and viral load reduction after HAART in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
17. 17. Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, and Mellors JW: Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T Cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999;179:329-336.
18. 18. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin B, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, and Kessler H: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-79.
19. 19. Merrill DP, Martinez-Picado J, Tremblay C, Sax, PE, Boswell SL, Wong JT, D'Aquila RT, Walker BD, and Hirsch MS: Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. J Infect Dis 1999;179:345-351.
20. 20. Malhotra U, Berrey MM, Huang Y, Markee J, Musey L, Schacker T, Corey L, and McElrath MJ: Effect of combination antiretroviral therapy on HIV-1-specific cellular immunity in acute HIV-1 infection. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, January 1999. [Abstract 23]
21. 21. Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, Pham B, Sun E, Leonard JM, and Cameron DW: Improvement in cell-mediated immune function during potent anti-HIV therapy with ritonavir plus saquivavir. J Infect Dis 1998;177: 898-904.
22. 22. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, and Picker LJ: Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry. J Clin Invest 1997;99:1739-1750.
23. 23. Cui Y and Chang LJ: Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis. BioTechniques 1997;22:1146-1149.
24. + T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells. J Clin Invest 1994;94:1947-1952.
25. 25. Fleury S, de Boer RJ, Rizzardi GP, Wolthers KC, Otto SA, Welbon CC, Graziosi C, Knabenhans C, Soudeyns H, Bart PA, Gallant S, Corpataux JM, Gillet M, Meylan P, Schnyder P, Meuwly JY, Spreen W, Glauser MP, Miedema F, and Pantaleo G: Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. Nature Med 1998;4:794-801.
26. 26. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, and McCune JM: Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Med 1999;5:83-89.
27. 27. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, and Schellekens PT: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998;4:208-214. [See comments].
28. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 1999;5:518-525.
29. 29. Mills HR and Jones IM: Expression and purification of p24, the core protein of HIV, using a baculovirus-insect cell expression system. AIDS 1990;4:1125-1131.
30. 30. Gross I, Hohenberg H, Huckhagel C, and Krausslich HG: N-terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles. J Virol 1998;72:4798-4810.
31. 31. Moore JP, McKeating JA, Weiss RA, and Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990;250:1139-1142.
32. 32. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
33. 33. Roux KH: Negative-stain immunoelectron-microscopic analysis of small macromolecules of immunologic significance. Methods 1996;2:247-256.
34. 34. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD, and Moore JP: Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997;71:2799-2809.
35. 35. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, and Moore JP: The relationship between T-proliferative responses and plasma viremia during treatment of HIV-1 infection with combination antiviral therapy. J Infect Dis (submitted).
36. 36. Ratto-Kim S, Sitz KV, Garner RP, Kim JH, Davis C, Aronson N, Ruiz N, Tencer K, Redfield RR, and Birx DL: Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T-cell proliferative response. J Infect Dis 1997;179:337-344.
37. 37. Weinberg A, Zhang L, and Brown D: Effect of cryopreservation on cell-mediated immunity assays. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, January 1999. [Abstract 450]
38. 38. Greco G, Fujimura SH, Mourich DV, and Levy JA: Differential effects of human immunodeficiency virus isolates on beta-chemokine and gamma interferon production and on cell proliferation. J Virol 1999;73:1528-1534.
39. 39. Wahren B, Rosen J, Sandstrom T, Matheison T, Modrow S, and Wigzell H: HIV-1 peptides induce proliferative response in lymphocytes of HIV-1-infected persons. J Acquir Immune Defic Syndr 1989;4:448-456.
40. 40. Wahren B, Matheison T, Rosen J, and Wigzell H: Common and unique T-cell epitopes of HIV-1. Vaccine 1989;89:89-93.